EUVIMEDEUVIMED entdecken
Open Access

Treat-to-Target Urate-Lowering Treatment and Cardiovascular Outcomes in Patients With Gout

Edoardo Cipolletta, Tatiana Zverkova Sandström, Davide Rozza, Clemence Leyrat, Georgina Nakafero, Panagiota Drivelegka, Anthony J Avery, Mamas A Mamas, Laila J Tata, Mats Dehlin, Abhishek Abhishek

JAMA Internal Medicine · 01.03.2026 · 186 (3) · 332

DOI: 10.1001/jamainternmed.2025.7453 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Internal Medicine, erschienen am 01.03.2026. Verfasst von Edoardo Cipolletta und 10 weiteren Autor:innen. Beteiligte Einrichtung: Academic Rheumatology, University of Nottingham, Nottingham, United Kingdom. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Gout, Gout Suppressants, Uric Acid. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Gout is associated with increased cardiovascular risk. Whether achieving a target serum urate level lower than 6 mg/dL with urate-lowering treatment (ULT) would reduce cardiovascular risk in patients with gout is unknown.

Objectives

To evaluate the association between achieving a serum urate treatment target lower than 6 mg/dL and cardiovascular events among patients with gout who were newly prescribed ULT. Design, Setting, and Participants This new-user cohort study using emulated target trial framework with up to 5-year follow-up was performed using primary care data from the Clinical Practice Research Datalink Aurum linked to hospitalization and mortality records from January 1, 2007, to March 29, 2021. Patients were 18 years or older, diagnosed with gout, had a pretreatment serum urate level higher than 6 mg/dL, and were newly prescribed ULT. Data were analyzed from May 2024 to January 2025. Exposure Patients were assigned to the treat-to-target (T2T) ULT arm or the non–T2T ULT arm if they achieved or did not achieve a serum urate level lower than 6 mg/dL, respectively, within 12 months of their first ULT prescription. Main Outcomes and Measures The primary outcome was first major adverse cardiovascular event within 5 years of first ULT prescription. Gout flare was the positive control outcome. Acute bronchitis, cataract, and appendicitis were included as negative control outcomes. Weighted absolute 5-year event-free survival and weighted hazard ratios (HRs) with 95% CIs were estimated.

Results

Of 109 504 patients included, the mean (SD) age was 62.9 (15.2) years, 22.2% were female, the mean (SD) disease duration was 2.5 (3.6) years, and 27.3% were included in the T2T ULT arm. Patients in the T2T ULT arm had a higher 5-year survival (weighted survival difference, 1.0%; 95% CI, 0.5%-1.6%) and lower risk of major adverse cardiovascular events (weighted HR, 0.91; 95% CI, 0.89-0.92) than those in the non–T2T ULT arm. There was a greater association for people at high and very high cardiovascular risk than those with moderate risk. Patients who achieved a lower serum urate target of less than 5 mg/dL had a larger risk reduction (weighted survival difference, 2.6%; 95% CI, 0.9%-3.6%; weighted HR, 0.77; 95% CI, 0.72-0.81). Patients in the T2T ULT arm had fewer gout flares. No differences were observed for negative control outcomes. Conclusions and Relevance In this cohort study among patients with gout who were newly prescribed ULT, achieving serum urate levels lower than 6 mg/dL within 12 months was associated with a lower 5-year risk of major adverse cardiovascular events.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiovascular DiseasesGoutGout SuppressantsUric AcidAgedFemaleHumansMaleMiddle AgedCohort StudiesTreatment Outcome

Substanzen

Gout SuppressantsUric Acid

Autor:innen und Institutionen

  • Academic Rheumatology, University of Nottingham, Nottingham, United Kingdom.
  • Department of Clinical and Molecular Sciences, Polytechnic University of Marche, Ancona, Italy.
  • Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
  • Epidemiology Unit, Italian Society for Rheumatology (SIR), Milan, Italy.
  • Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, United Kingdom.
  • Centre for Academic Primary Care, School of Medicine, University of Nottingham, Nottingham, United Kingdom.

Zitieren

APA

Cipolletta, E., Zverkova Sandström, T., Rozza, D., Leyrat, C., Nakafero, G., Drivelegka, P., Avery, A. J., Mamas, M. A., Tata, L. J., Dehlin, M., & Abhishek, A. (2026). Treat-to-Target Urate-Lowering Treatment and Cardiovascular Outcomes in Patients With Gout. JAMA Internal Medicine, 186(3), 332. https://doi.org/10.1001/jamainternmed.2025.7453

Vancouver

Cipolletta E, Zverkova Sandström T, Rozza D, Leyrat C, Nakafero G, Drivelegka P, et al. Treat-to-Target Urate-Lowering Treatment and Cardiovascular Outcomes in Patients With Gout. JAMA Internal Medicine. 2026;186(3):332. doi:10.1001/jamainternmed.2025.7453

BibTeX
@article{Cipolletta2026,
  author = {Cipolletta, Edoardo and Zverkova Sandström, Tatiana and Rozza, Davide and Leyrat, Clemence and Nakafero, Georgina and Drivelegka, Panagiota and Avery, Anthony J and Mamas, Mamas A and Tata, Laila J and Dehlin, Mats and Abhishek, Abhishek},
  title = {Treat-to-Target Urate-Lowering Treatment and Cardiovascular Outcomes in Patients With Gout},
  journal = {JAMA Internal Medicine},
  year = {2026},
  volume = {186},
  number = {3},
  pages = {332},
  doi = {10.1001/jamainternmed.2025.7453}
}
Kostenlos starten →